Antifungal drug, Ibrexafungerp, for the treatment of vaginal yeast infection, progresses to late stage development

SCYNEXIS, Inc., a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that it has completed patient enrollment in its global Phase 3 VANISH-306 study to evaluate the safety and efficacy of oral ibrexafungerp as a treatment for women with vulvovaginal candidiasis (VVC), commonly referred to as vaginal yeast infection. Ibrexafungerp, ["]

The post Antifungal drug, Ibrexafungerp, for the treatment of vaginal yeast infection, progresses to late stage development appeared first on Outbreak News Today.